BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan · Delayed Price · Currency is TWD 33.75
-0.20 (-0.59%)
Mar 24, 2026, 1:30 PM CST
BioGend Therapeutics Revenue
In the year 2025, BioGend Therapeutics had annual revenue of 222.34M TWD with 32.62% growth. BioGend Therapeutics had revenue of 60.49M in the quarter ending December 31, 2025, with 19.59% growth.
Revenue
222.34M
Revenue Growth
+32.62%
P/S Ratio
18.88
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 222.34M | 54.69M | 32.62% |
| Dec 31, 2024 | 167.65M | 57.74M | 52.53% |
| Dec 31, 2023 | 109.91M | 78.46M | 249.51% |
| Dec 31, 2022 | 31.45M | 22.18M | 239.26% |
| Dec 31, 2021 | 9.27M | 7.88M | 565.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medigen Biotechnology | 1.58B |
| Genovate Biotechnology | 492.41M |
| Sagittarius Life Science | 346.08M |
| Pharmosa Biopharm | 67.27M |
| OBI Pharma | 58.58M |
| ACRO Biomedical | 36.50M |
| UnicoCell Biomed | 30.10M |
| Formosa Pharmaceuticals | 9.50M |